Fulcrum Asset Management LLP bought a new position in shares of Revvity Inc. (NYSE:RVTY – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,366 shares of the company’s stock, valued at approximately $514,000.
A number of other institutional investors and hedge funds have also recently made changes to their positions in RVTY. Pillar Financial Advisors LLC acquired a new stake in shares of Revvity in the 3rd quarter valued at approximately $29,000. Heritage Family Offices LLP bought a new stake in shares of Revvity during the 3rd quarter valued at approximately $37,000. Root Financial Partners LLC bought a new stake in shares of Revvity during the 3rd quarter valued at approximately $64,000. Global Retirement Partners LLC acquired a new position in Revvity during the 2nd quarter worth approximately $51,000. Finally, EverSource Wealth Advisors LLC increased its position in Revvity by 17.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.
Revvity Stock Performance
Shares of RVTY stock opened at $154.60 on Monday. The firm has a market capitalization of $17.26 billion, a price-to-earnings ratio of 68.41, a PEG ratio of 2.70 and a beta of 1.08. The company has a current ratio of 2.65, a quick ratio of 2.10 and a debt-to-equity ratio of 0.36. The business’s 50-day moving average price is $150.48 and its 200-day moving average price is $114.30. Revvity Inc. has a 12 month low of $81.22 and a 12 month high of $171.74.
Revvity (NYSE:RVTY – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.08. Revvity had a return on equity of 8.64% and a net margin of 8.61%. The company had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. During the same quarter in the prior year, the firm posted $1.18 earnings per share. The firm’s revenue was up 4.3% compared to the same quarter last year. Equities research analysts forecast that Revvity Inc. will post 5.42 EPS for the current year.
Revvity Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Investors of record on Friday, January 22nd will be given a dividend of $0.07 per share. The ex-dividend date is Friday, January 22nd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio (DPR) is currently 12.39%.
Insider Buying and Selling
In other Revvity news, insider Tajinder S. Vohra sold 7,330 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the transaction, the insider directly owned 6,635 shares in the company, valued at approximately $934,738.80. This represents a 52.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the firm’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the transaction, the insider directly owned 14,781 shares of the company’s stock, valued at $2,136,297.93. The trade was a 9.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 9,045 shares of company stock worth $1,281,439 over the last three months. Insiders own 0.85% of the company’s stock.
Analyst Ratings Changes
Several equities analysts recently commented on RVTY shares. Sanford C. Bernstein reissued a “market perform” rating on shares of Revvity in a research note on Thursday. Evercore reaffirmed an “outperform” rating on shares of Revvity in a research note on Wednesday, August 5th. TD Cowen upped their price target on shares of Revvity from $175.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Wall Street Zen upgraded shares of Revvity from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Barclays increased their price target on Revvity from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 4th. Six analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $133.86.
Read Our Latest Stock Analysis on RVTY
About Revvity
Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company’s work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.
See Also
- Five stocks we like better than Revvity
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY – Free Report).
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
